Perspective from William B. Trattler, MD
April 19, 2016
1 min read
Save

FDA approves Avedro’s cross-linking system for progressive keratoconus

Perspective from William B. Trattler, MD
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA has approved the KXL System and two photoenhancers for corneal collagen cross-linking treatment of progressive keratoconus, according to a press release from Avedro.

The photoenhancers are Photrexa 0.146%, a riboflavin 5’-phosphate solution, and Photrexa Viscous 0.146%, a riboflavin 5’-phosphate in 20% dextran ophthalmic solution.

“We plan to begin taking orders for the KXL System immediately and plan to begin shipping our Photrexa products in the next few months as we ramp up our drug manufacturing,” Brian Roberts, chief operating and financial officer for Avedro, said in the release.

The approval was based on data from three prospective, randomized, parallel-group, open-label, placebo-controlled 12-month trials conducted in the U.S. to determine safety and effectiveness, the release said.

 For more information: 

VIDEO: Cross-linking technique successfully applied to corneal infections

VIDEO: Surgeon anticipates FDA approval of collagen cross-linking for treatment of keratoconus, ectasia

VIDEO: Advances in corneal collagen cross-linking